Pharma & Biotech AI News: How AI Agents Replaced 3 Hours of Daily Analyst Work

I’ve spent over 20 years in competitive intelligence, mostly in pharma and biotech. We’re working with the majority of the top 10 pharmaceutical companies. And the single biggest operational problem we’ve faced — the one that eats more analyst hours than anything else — is pharma and biotech news monitoring.

Not because the work is hard. Because there’s just too much of it.

What we did is that we built our own AI team for global CI monitoring and alert writing. I want to walk you through why we had to, how we did it, what works, and — just as importantly — what doesn’t. Because there’s a lot of hype in this space, and what I want to share is what we’ve actually learned by doing it.


The Problem: Clients Want More, and Your Team Is Already Drowning

Here’s the reality every CI team is living right now: the clients are expecting more for the same dollar.

When we think about news monitoring, if before we’re tracking US and Europe, 5 competitors, now they’re expecting to see a lot more markets being covered. And they’re expecting to see a lot more competitors being covered for the relevant news. The scope has exploded, but the budgets haven’t. And neither has the number of analysts on your team.

Before we started automating, pharma AI news monitoring took about 3 hours per day per analyst. Three hours just to scan sources, identify what’s relevant, categorize it, and start writing something useful. That’s nearly half the workday gone before anyone does actual analysis.

And the problem compounds from there.

The News Flood

One of the areas where we spent quite a bit of time from the team was grading CI alerts. The news — there’s a lot of news outlets, there’s a lot of information coming. And then we need to identify the right news, and then be able to write the alert. Every day, your team is sifting through hundreds of items across regulatory filings, clinical trial updates, earnings calls, patent filings, conference abstracts, trade press — trying to figure out which ones actually matter to your clients’ Key Intelligence Questions.

And if you’re covering biotech alongside big pharma, the volume multiplies. Now you’re also tracking biotech funding rounds, IPO filings, M&A announcements, and early-stage pipeline signals from companies that didn’t exist two years ago. A Series B raise by a biotech in your therapeutic area might not make the front page of Scrip, but it could signal a future competitor — or a future acquisition target.

Most of it doesn’t matter. But you can’t know that until someone reads it. That’s the trap.

The Language Problem

As soon as I think about multiple countries, then it also means the document needs to be translated from a foreign language to English. So then you’re adding additional steps on how you process that information. A Japanese regulatory filing. A German medical journal article. A Chinese clinical trial update. Each one needs to be translated before anyone on the team can even assess whether it’s relevant. And if you don’t cover those sources? You miss signals that your competitors’ local teams caught months ago.

The Friday Evening Problem

News doesn’t stop when your team goes home. A competitor announces a Phase III AI partnership at 6 PM on a Friday. By Monday, your stakeholders have already seen it — from a client, a board member, a LinkedIn post. The CI team wasn’t first to know. They weren’t even second. That erodes credibility in ways that take months to rebuild.

The Personalization Gap

Here’s another pain point that doesn’t get talked about enough: most monitoring systems send the same alerts to everyone. The oncology lead gets cardiology news. The commercial VP gets early-discovery updates. Nobody gets exactly what they need.

What we realized is that the alerts should not be based on keywords — they should be based on the intelligence question. The way that the email reaches your inbox should be based on the questions that you had at the beginning. So it’s very customizable based on your intelligence needs. If you want a summary in just 5 bullet points, you can do that. If you want a summary with 3 bullet points, background information, and then other relevant news, we can set it up that way.

But doing that manually? Having a human analyst curate personalized alerts for every stakeholder? That doesn’t scale. Not without consuming the entire team’s capacity.

Tool Sprawl

To cover all these sources, most CI teams cobble together five to ten different tools: a news aggregator, a clinical trial tracker, a patent monitoring service, a social listening platform, email alerts. None of them talk to each other. None of them understand your intelligence requirements. Each one generates its own stream of semi-relevant results that someone has to manually synthesize.

And even the purpose-built platforms have gaps. Search platforms like AlphaSense are excellent at finding information fast, but they deliver raw content — the interpretation is on you. Data platforms like IQVIA and GlobalData have unmatched structured datasets, but their news monitoring is bolted on, not core. News aggregators like Contify collect and categorize news, but they stop short of writing the actual analysis. Editorial services like Citeline’s Scrip produce excellent journalism, but a Scrip article is the same article for every subscriber — it doesn’t answer your specific intelligence questions or deliver the alert in the format your stakeholders need.

The market has search tools, data tools, and content tools. What it didn’t have — and what we needed — was a system where AI agents actually read, categorize, analyze, and write the CI alert, personalized to each stakeholder’s intelligence questions, in the format they prefer, in under 20 minutes, in any language.

This is the environment CI teams are operating in. And this is why we had to build something different.

For the broader context on what a structured CI function looks like, see our guide on how to build a CI program.


What Changed: The Math That Made Us Move

Before we get into how we built it, I want to share the numbers that convinced us this was possible. Because the economics of AI for information processing aren’t incremental — they’re a category shift. And in biotech, where things move even faster than big pharma — a funding round or partnership announcement can shift competitive dynamics overnight — the case for automation is even more urgent. You can’t afford to have an analyst spending three hours on monitoring when a biotech startup just announced a platform deal that changes the competitive landscape in your indication.

Reading Speed

If we look at GPT-4o — last time I checked the pricing — and we look at the speed, what we saw is that GPT-4o will process 1 million tokens, which is about 10 books, in less than a minute. It only costs $2.50.

If I were to ask a human to read 10 books, it would take them at least 8 business days without stopping. And if we look at a $20 per hour average rate for a knowledge worker, then it would cost about $1,200 to read those 10 books.

So what we’re saying here is that if you use an LLM to process information, you can get that done 5,000 times faster. And 500 times cheaper than a human.

For pharma and biotech news monitoring, where the job is essentially reading enormous volumes of text and deciding what matters, those numbers change everything.

Writing Speed

And then we talk about writing — being able to extract the data and then summarize it. If we were to write 10 books with GPT-4o, it would take about 2 hours and cost $10. If we were to do that with a human, it would take about 50 business days just typing — not even thinking about what the content is going to be, just typing. That’s 50 business days, or approximately $8,000.

The LLMs are 600 times faster than human writing, and at least 800 times cheaper.

The Summarization Breakthrough

This was the big one for us. Even in early studies comparing Claude 3 versus a human at summarizing, the LLMs were already doing a better job to summarize content.

And for us, that was huge, because if you think about competitive intelligence and knowledge work, a lot of the time-consuming part is really finding those nuggets of information within an investor report, within an SEC filing, and being able to extract that. Before, it took hours. Now we can do that within minutes or seconds.

That’s not a marginal improvement. That’s a fundamental change in what’s possible for a CI team. The bottleneck shifts from “can we process enough information?” to “are we asking the right questions?”


How We Built It: From Make.com to Production

I want to be transparent about the journey because I think it’s instructive. We didn’t start with some massive platform. We started with duct tape and curiosity.

Version 0.1: The Make.com Prototype

The first thing that we did was just Make.com. If you’re not aware of it, highly recommend — go on YouTube, there’s a lot of tutorials. We built a workflow where we connected Make.com to an RSS feed — in this case, our own internal platform. And then we had an OpenAI agent to look at whether the news was relevant. We put all that into an Excel spreadsheet.

Then we had another agent that would go there and tag the news — was it regulatory, was it commercial, was it partnering? A very simple agent. That would update the Excel file, and then we had a summarizer agent that would create a quick summary of that particular news. And then we had a router — if the news was regulatory, it would send it to this specific workflow.

And that was considered version 0.1. That allowed us to see: okay, the models are working, we’re getting pretty good results. It’s not perfect. But at least we moved in that direction.

That prototype taught us something critical: the more specific the task is, the better the quality of the LLM in achieving that specific task. That became our key design principle. Don’t ask one AI to do everything. Break the work into discrete, well-defined tasks and assign each one to a specialized agent.

Breaking It Down: One Agent, One Job

Based on what we learned, we started breaking the workflow into specialized agents:

So a regulatory update gets summarized differently than a commercial announcement, which gets summarized differently than a clinical trial result. Each agent is tuned for its specific output format.

Then we had agents that would write the actual alert, incorporate background information, and route the finished product to the right stakeholders.

Bringing It In-House

At that point, we started to bring that in-house. The Make.com prototype proved the concept, but to serve pharmaceutical clients at scale — with the security, reliability, and customization they need — we needed our own infrastructure.

What we built is an agentic workflow. One agent removes duplicates. Another identifies relevant news. A third maps it against KITs and KIQs. If it’s alert-worthy, a series of agents summarize it, write the alert, and send it out. Each agent has a single, well-defined job. We were able to do all of this with off-the-shelf tools — the insight wasn’t in the technology, it was in the architecture.

This agent team is both internal agents that we’ve built and also partners with other companies that provide these services — this multi-agent collaboration to make sure that we deliver the alerts.

For more on how AI-powered CI works in practice, we’ve written a detailed guide on the approach.


How It Works Now: 100% Coverage, Intelligence-Driven Alerts

Here’s what the system looks like in production today.

Complete Source Coverage

We have a platform where we have 24/7 company coverage. I’ll put it at 100%, because it’s not built only on our web crawlers — it’s built also on all the different data providers and APIs that we subscribe to.

If one of the news APIs that we have doesn’t cover a specific company, then we can build a specific web crawler. So for our clients now, we can provide 100% coverage. That’s a claim most monitoring platforms can’t make, because they’re limited to their own data partnerships. We supplement with custom crawlers wherever there’s a gap.

This is especially important for biotech tracking. Big pharma companies are well-covered by every major news source, but emerging biotechs — the Series A startup with a novel modality, the spinout from an academic lab — often fly under the radar of standard news APIs. These are the early-stage competitors that big pharma CI teams often miss entirely until they show up with Phase II data or get acquired. Our custom crawling fills that gap.

Adjustable Crawling for Key Events

This is something that matters a lot in pharma: we can specify the time that each crawler needs to go out and check the news. So if there’s a key event coming up — a product launch, an FDA decision, a competitor’s earnings call — we can increase the crawling rate. Instead of waiting whenever the API sends you the push, now we can go to that website every 5 minutes, every 10 minutes, every 15 minutes to see: has the news come out, and what does the news say?

For pharma and biotech news specifically, this is critical during conference seasons (ASCO, ESMO, JPM), PDUFA dates, and competitor earnings weeks. The difference between catching a signal in 5 minutes versus 5 hours can be the difference between briefing your executive before a board call and briefing them after.

Intelligence-Question-Driven Alerts

I keep coming back to this because it’s the most important design decision we made: the alerts are not based on keywords. They’re based on the intelligence question.

The way the alert reaches your inbox is based on the questions that you defined at the beginning. So it’s very customizable based on your intelligence needs. This means two clients tracking the same competitor can get completely different alerts — because they’re asking different questions about that competitor.

This is what separates AI-powered pharma and biotech news monitoring from a glorified Google Alert — or even from sophisticated search platforms that let you build watchlists and set keyword-based notifications. Keywords catch words. Intelligence questions catch meaning. Two clients tracking the same competitor can get completely different alerts because they’re asking different questions about that competitor. That level of personalization simply isn’t possible with platforms that treat monitoring as a search feature rather than an intelligence operation.

Personalized Output Formats

The alert is written as you want it, as the client wants it. If you want a summary in just 5 bullet points, you can do that. If you want a summary with 3 bullet points, background information, and then other relevant news, we can also set it up that way.

Different stakeholders at the same company get different formats. The head of oncology gets detailed clinical breakdowns. The commercial lead gets market impact assessments. The CSO gets strategic pattern analysis. All from the same underlying pharma and biotech news stream, all processed by the same agent team, all tailored to the reader.


What AI Can and Can’t Do: The Honest Assessment

This is the section most vendors skip. I’m not going to, because understanding the limitations is what separates a CI team that uses AI effectively from one that gets burned by it.

Where AI Is Already Excellent: FYI Summaries

How close is the output to an alert written by an experienced CI analyst? If the news is just an FYI — a quick summary of what happened — I’d say 90%, 100% good. The AI can read the source, extract the key facts, structure them clearly, and deliver them faster than any human. For straightforward pharma and biotech news — a partnership announcement, a regulatory filing, a clinical trial update, a biotech funding round — the AI output is production-ready with minimal human touch.

Where Humans Are Still Essential: Implications

If the news now needs to incorporate background information, needs to incorporate implications — what does it mean to the organization — then there, you still have a big component of human intervention. I’ll say probably the AI can get it to 60, 70, maybe 80%, but you still need that 20-plus percent of a human to finalize it.

The implications cannot be done by the AI, because they don’t have the context. They don’t know that this competitor’s CEO mentioned this therapeutic area three times in the last earnings call. They don’t know that your client’s board just approved a budget for this exact indication. They don’t know the political dynamics inside the organization that make this news a big deal versus a footnote.

That context — the stuff that lives in an experienced analyst’s head — is what makes the difference between information and intelligence. And that’s still a human job. For more on this distinction, see our guide on competitive intelligence fundamentals.

The Hallucination Problem

Let’s talk about hallucination. In 2023, all major LLMs — 91% of them had hallucinated. That means you ask a question and you still get the wrong answer. For biopharma news monitoring, where accuracy is non-negotiable, this is a serious concern.

The AI might confidently state that a drug is in Phase III when it’s actually in Phase II. It might attribute a quote to the wrong executive. It might conflate two different clinical trials. These aren’t theoretical risks — they’re things we’ve caught and had to build safeguards against.

Performance Degradation

Here’s something that doesn’t get talked about enough: we’ve seen that quite a bit with our platform — the LLMs start to degrade. You get very good answers, you build on Make.com, you get your workflow, amazing. Next week, you’re getting different results. The LLM is getting degraded — they made some changes on the backend, you’re not aware of it, and then your performance goes down.

This is why you can’t just build a pharma and biotech news monitoring system and walk away. You need continuous evaluation. You need to be watching the output quality every day.

The Triangulation Approach

One of the approaches we use is to get an LLM from Google, an LLM from Anthropic, an LLM from OpenAI, ask the same question to all three of them, and then whichever gives you the consistent answer — that’s most likely the right answer.

It’s not elegant. It costs more. But for high-stakes pharma and biotech news where getting a fact wrong can damage your credibility with a top-10 pharma client, the redundancy is worth it.


Quality Control: How We Keep the Output Trustworthy

Quality isn’t a feature — it’s the whole game. Here’s how we approach it.

The Evaluation Framework

We’ve built an evaluation system that measures four dimensions of every alert:

That completeness number — 82% — is honest. It’s the hardest one to improve because completeness often requires the kind of background context and implication-drawing that AI still struggles with. We’re working on it, but I’d rather share the real number than pretend we’re at 99%.

LLM-as-Judge + Human Expert

We use a two-layer quality system. First, we use LLMs to evaluate the output of other LLMs — checking for factual consistency, source attribution, and structural quality. Then human experts review a sample of alerts to validate the AI’s judgment and catch the things that automated evaluation misses.

The Scrum Process

The way we work at Avizum is using Scrum Agile, so there are multiple people looking at the deliverables before they go out to the client. That ensures there is triangulation within the organization.

Anything that goes to the client is reviewed by a human. Full stop. If something goes directly from the news monitoring platform to the client without human review, then that’s clearly labeled as generated by AI, so the end user knows that a human has not reviewed it.

That transparency is non-negotiable. Our clients trust us because we’re honest about what the AI did and what a human did.

The Cassette Model: Swapping LLMs

The way you need to think about it is — once you build the workflow, you can think about it like cassettes, or something that you plug in and plug out. As soon as a new model comes in, you plug it in. If you have the right evaluation and the right metrics, then you can see if a new model is going to perform better than the old model.

This is critical because the AI landscape moves fast. A model that was best-in-class six months ago might be outperformed by three alternatives today. Our architecture lets us swap models without rebuilding the workflow. The agents, the routing, the personalization — all of that stays the same. Only the underlying model changes.

We test every new model against our evaluation framework before deploying it. No gut feelings. No hype-driven switches. Data.


The Economics: What This Actually Saves

Let me put real numbers on what this means for a CI team.

Time Savings

Before automation, pharma and biotech news monitoring took about 3 hours per day per analyst. Now there’s less than an hour. And within that hour, we can do a lot more coverage — more markets, more competitors, more therapeutic areas.

For a team of four analysts, that’s roughly 8 hours per day freed up. Eight hours that can go into the work that actually requires human intelligence: stakeholder advisory, competitive intelligence analysis, war gaming, strategic recommendations.

Cost Reduction

For most CI teams, deploying AI for news monitoring reduces the total cost of continuous pharma and biotech news coverage by approximately 60% — while simultaneously expanding the breadth and depth of coverage. You’re paying less and getting more. That’s a conversation every CI leader can win with their CFO.

The Declining Cost Curve

Here’s why we’re betting big on this direction: over the last years, the energy required to produce one token — which is the unit of measure for LLMs — has decreased by 45,000x.

What that means is that even though a process today with AI might feel expensive at scale, we’re betting that in the next 2–3 years, the same process will become a lot cheaper because of the efficiency that these companies are putting into their models. The economics that already work today are going to get dramatically better.

By 2027, the cost of running comprehensive global pharma and biotech news monitoring with AI will be a fraction of what it costs now. The teams that build the systems today will capture that cost decline automatically. The teams that wait will still be paying 2024 prices for manual processes.


What’s Next: Where We’re Headed

We’ve solved the monitoring and alerting layer. But there’s a lot more to build.

Memory and Context

The next frontier is giving the AI agents persistent memory — so they remember that this competitor mentioned this therapeutic area three times in the last quarter, or that this regulatory pathway has been trending in a specific direction. Right now, each alert is processed independently. Adding memory will allow the system to surface patterns and trends that no single alert can capture.

Better Evaluation

We’re investing heavily in automated evaluation frameworks. As the models get better, our ability to measure “better” needs to keep pace. That means more sophisticated benchmarks, more diverse test cases, and tighter feedback loops between evaluation results and model selection.

Data Quality and Vectorized Storage

The quality of the AI’s output is directly tied to the quality of the data going in. We’re building better data pipelines — cleaner ingestion, smarter deduplication, more structured storage. Vectorized storage will let us do semantic search across our entire news corpus, so when an analyst asks “what has this competitor said about AI in the last 6 months?”, the system can pull every relevant mention instantly.

Guardrails and Security

Working with top-10 pharma means working under their security and compliance requirements. We’re building more robust guardrails — not just for hallucination prevention, but for data handling, access control, and audit trails. Every alert needs to be traceable. Every data source needs to be documented. Every model decision needs to be explainable.

The B2C Opportunity

The business has been B2B — meaning that we work directly with pharma. We believe we have a tool that maybe is of interest to people like yourself — a B2C-type model. CI professionals, analysts, consultants, and researchers who need pharma and biotech AI news monitoring but don’t have a top-10 pharma budget. We’re exploring how to make this accessible to a broader audience.

For teams looking to build their own CI automation capability, the technology is more accessible than ever. The key is starting simple, iterating fast, and being honest about what works and what doesn’t.


The Bottom Line

Here’s what I’d tell any CI leader who’s still on the fence about AI for pharma and biotech news monitoring:

Start small. We started with Make.com and an Excel spreadsheet. That was version 0.1. It wasn’t perfect, but it proved the concept and showed us where to invest next.

Break the work into specific tasks. The more specific the task, the better the quality of the LLM. Don’t try to build one magic agent that does everything. Build a team of specialists.

Be honest about the limitations. The AI can get you to 60, 70, maybe 80% on complex alerts that need implications and context. That last 20% is where your experienced analysts earn their keep. That’s not a failure of AI — that’s a successful reallocation of human talent to the work that matters most.

Measure everything. Build evaluation frameworks. Track performance over time. Watch for degradation. Swap models when the data tells you to, not when the hype tells you to.

And most importantly: the goal isn’t to replace your CI team. It’s to give them superpowers. Before, 3 hours a day went to scanning and summarizing. Now, that’s less than an hour — and within that hour, we can cover far more ground. The analysts spend their time on analysis, advisory, and strategy. That’s what they were hired for. That’s what they’re best at.

The pharma and biotech news landscape is only getting denser. The teams that have built systematic, AI-powered monitoring capabilities will have an expanding advantage over those still relying on manual processes. The economics are already compelling, and they’re getting better every quarter.

We’ve been on this journey for years now. We’ve made mistakes, iterated, rebuilt, and learned. What I’ve shared here is the unvarnished version. If you want to talk about how this might work for your team, reach out to us at Avizum.


Frequently Asked Questions

What is pharma and biotech AI news monitoring, and why do CI teams struggle with it?

Pharma and biotech AI news monitoring is the process of tracking, filtering, and analyzing the flood of AI-related developments across the pharmaceutical and biotechnology industries — from drug discovery partnerships and regulatory AI guidance to biotech funding rounds and commercial AI deployments. CI teams struggle because the volume is overwhelming (thousands of items per week across multiple languages), clients expect more coverage for the same budget, and manual processes that worked five years ago can’t keep pace. What used to require tracking 5 competitors in 2 markets now means covering dozens of competitors — including emerging biotechs — across global markets.

How much time does AI save in pharma and biotech news monitoring?

In our experience, AI reduces daily monitoring time from about 3 hours per analyst to less than 1 hour — while simultaneously expanding coverage to more markets, more competitors, and more therapeutic areas. That’s roughly a 60% cost reduction with significantly broader and deeper coverage.

Can AI write CI alerts as well as an experienced analyst?

For straightforward news summaries — what we call FYI alerts — the AI gets it 90–100% right. For alerts that require background context, competitive implications, and strategic interpretation, the AI gets to about 60–80%. The implications still need human input because the AI doesn’t have the organizational context, stakeholder relationships, and strategic awareness that an experienced analyst brings. We always have humans review client-facing alerts, and anything delivered directly by AI is clearly labeled as such.

How do you handle AI hallucination in pharma news alerts?

Three ways. First, we use LLM triangulation — asking the same question to multiple models (Google, Anthropic, OpenAI) and validating consistent answers. Second, we run automated evaluation that checks factual consistency against source material (currently scoring 98%). Third, everything client-facing gets human review before delivery. We also monitor for performance degradation, since models can quietly get worse after backend updates.

What’s the difference between keyword-based monitoring and intelligence-question-based monitoring?

Keyword monitoring catches words — if “AI” and “oncology” appear in the same article, you get an alert, whether it’s relevant to your specific competitive questions or not. Intelligence-question-based monitoring is built around your actual KITs and KIQs. The system evaluates whether a news item answers one of your defined intelligence questions, then routes it to the right stakeholder in the right format. Two clients tracking the same competitor can get completely different alerts because they’re asking different questions.

How fast can AI deliver a pharma news alert?

We can configure crawling rates down to every 5 minutes for key events — FDA decisions, product launches, competitor earnings. From the moment news is published to a contextualized, personalized alert in a stakeholder’s inbox, the turnaround is typically under 20 minutes. During key events, we increase the crawling rate so we’re checking sources every 5–15 minutes instead of waiting for API pushes.

How do you keep up with new AI models?

We use what I call the cassette model — the workflow architecture stays the same, but you can plug in and plug out different LLMs. When a new model comes out, we test it against our evaluation framework (Factual Consistency, Title Accuracy, Quality/Readability, Completeness). If it outperforms the current model, we swap it in. No gut feelings, no hype — just data.

How is biotech news monitoring different from pharma news monitoring?

The core workflow is the same, but biotech adds layers of complexity. Big pharma companies are well-covered by every major news aggregator and data provider — biotech often isn’t. You need custom crawlers for emerging companies that standard APIs miss entirely. Biotech also moves faster: a Series B funding round, a platform licensing deal, or an IPO filing can reshape the competitive landscape in a therapeutic area overnight. And the signal-to-noise ratio is different — there are hundreds of biotechs in any given indication, and knowing which ones actually matter to your client’s competitive position requires intelligence-question-driven filtering, not just keyword matching. Our system handles both, but the biotech side is where automated coverage really earns its keep, because that’s where human analysts are most likely to miss early signals.

Can smaller CI teams or independent analysts use this kind of system?

We’re exploring that. The business has been B2B — working directly with pharma companies — but we believe the tool could serve a B2C audience: CI professionals, consultants, and researchers who need comprehensive pharma and biotech AI news monitoring without a top-10 pharma budget. For teams looking to start on their own, begin with Make.com or a similar workflow tool, connect it to your key news sources, and build specialized agents for each step (deduplication, relevance scoring, summarization). That’s exactly how we started. For a step-by-step guide, see How to Build a CI Program.